Article
Medicine, Research & Experimental
Yi-nuo Li, Yuan-yuan Li, Shi-xuan Wang, Xiang-yi Ma
Summary: This study aimed to explore the value of M701 in the immunotherapy of ovarian cancer ascites. The expression of EpCAM in ovarian cancer tissues was analyzed, and the effects of M701 on tumor cells and immune cells were examined. The results showed that M701 had a significant killing effect on tumor cells and could induce T cell activation.
CURRENT MEDICAL SCIENCE
(2023)
Article
Oncology
Peter Ruf, Hartwig W. Bauer, Alexandra Schoberth, Claudia Kellermann, Horst Lindhofer
Summary: Intravesical administration of catumaxomab in patients with EpCAM-positive recurrent non-muscle invasive bladder cancer has shown to be effective in eliminating tumor cells and increasing recurrence-free intervals without causing significant toxicity. Further clinical development of catumaxomab in this indication is warranted.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Multidisciplinary Sciences
Ying Zhang, Xuemei Xie, Pourya Naderi Yeganeh, Dian-Jang Lee, David Valle-Garcia, Karla F. Meza-Sosa, Caroline Junqueira, Jiayu Su, Hongbo R. Luo, Winston Hide, Judy Lieberman
Summary: New cancer immunotherapy strategies using EpCAM aptamer-linked small-interfering RNA chimeras (AsiCs) were effective in selectively knocking down genes in EpCAM(+) tumors to enhance immune recognition. Four of the six AsiC (Upf2, Parp1, Cd47, and Mcl1) were able to inhibit tumor growth and improve tumor-infiltrating immune cell functions. AsiC mixtures showed better efficacy than individual AsiC and could synergize with anti-PD-1 checkpoint inhibition.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Medicine, General & Internal
Ce Wang, Shang Chen, Yingjuan Wu, Di Wu, Jingbo Wang, Furong Li
Summary: This study successfully demonstrated a dual-target therapy strategy for lung cancer using two bispecific antibodies, showing a superior antitumor effect. The combination therapy inhibited the growth of lung cancer by enhancing CTL and inducing the production of type I interferons, while also significantly regulating T cell populations in TDLNs.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Article
Immunology
Roya Mirzaei, Soodabeh Shafiee, Rana Vafaei, Malihe Salehi, Neda Jalili, Zahra Nazerian, Ahad Muhammadnajad, Fatemeh Yadegari, Mohamad Reza Esmailinejad, Leila Farahmand
Summary: Researchers successfully cloned and expressed an anti-EpCAM scFv antibody for breast cancer treatment. The recombinant antibody showed specific binding to malignant breast cancer cells and inhibited their migration and invasion ability. In vivo experiments with mouse models showed significant suppression of tumor growth and reduction in blood supply in response to the recombinant antibody intervention. These findings suggest that the antibody could be a therapeutic tool for reducing invasion and proliferation in malignant breast cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Jingshu Meng, Xiao Yang, Jing Huang, Zhan Tuo, Yan Hu, Zhiyun Liao, Yu Tian, Suke Deng, Yue Deng, Zhiyuan Zhou, Jonathan F. Lovell, Honglin Jin, Yang Liu, Kunyu Yang
Summary: This study presents an injectable hydrogel drug delivery system based on chitosan hydrochloride and oxidized dextran (CH-OD) for loading sulfasalazine (SSZ) to effectively treat malignant ascites in advanced hepatocellular carcinoma (HCC). The CH-OD-SSZ hydrogel exhibits enhanced cytotoxicity and immunogenic ferroptosis compared to free SSZ. In preclinical models, the intraperitoneal administration of CH-OD-SSZ hydrogel significantly suppresses tumor progression, repolarizes macrophages, activates dendritic cells, and achieves ascites regression when combined with anti-PD-1 immunotherapy.
Article
Pharmacology & Pharmacy
Si Chen, Shuang Zhang, Yifan Wang, Xin Yang, Hong Yang, Chunying Cui
Summary: GO modified with chitosan and anti-EpCAM monoclonal antibody as a siRNA carrier showed excellent biosafety and tumor targeting effect. GCE/siRNA exhibited superior protection effect for survivin-siRNA and significant gene silencing ability in vitro.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Biology
Yan Feng, Kun Xie, Yanxin Yin, Bingyu Li, Chenyu Pi, Xiaoqing Xu, Tao Huang, Jingming Zhang, Bo Wang, Hua Gu, Jianmin Fang
Summary: B7-H3 plays a crucial role in tumor progression and is associated with overexpression in various solid tumors, advanced stages, poor clinical outcomes, and resistance to therapy. Researchers have developed a novel anti-B7-H3 x anti-CD3 bispecific antibody that exhibits potent cytotoxic activity against B7-H3-positive tumor cells by improving T cell activation and proliferation. This bispecific antibody also shows strong antitumor activity in animal models.
Article
Oncology
Valentina Palacio-Castaneda, Bas van de Crommert, Elke Verploegen, Mike Overeem, Jenny van Oostrum, Wouter P. R. Verdurmen
Summary: Researchers have developed modular engineered proteins that can selectively degrade Ras in tumor cells that overexpress EpCAM, using endopeptidases fused with either Pseudomonas aeruginosa exotoxin A or diphtheria toxin. These proteins showed effective Ras degradation and selective toxicity towards tumor cells in both 2D and 3D tumor models, while non-cancerous fibroblasts remained unaffected.
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Article
Oncology
Minhua Chen, Yutong Li, Yu Wu, Siqi Xie, Jie Ma, Jingjing Yue, Rong Lv, Zhigang Tian, Fang Fang, Weihua Xiao
Summary: NK cells have shown great potential in targeting various cancers, especially hematological malignancies, but their efficacy against solid tumors is limited. This study demonstrates that NK cells expanded using a feeder cell-free system derived from peripheral blood mononuclear cells have potent inhibitory effects on ovarian cancer growth. Adoptive transfer of expanded NK cells can reduce ascites formation and inhibit tumor growth in ovarian cancer mouse models. This highlights the promise of NK cell immunotherapy as a treatment strategy for ovarian cancers, including solid tumors and ascites.
Article
Immunology
Mary L. Faber, Robyn A. A. Oldham, Archana Thakur, Mary Jo Rademacher, Ewa Kubicka, Theresa A. Dlugi, Steven A. Gifford, William M. Mckillop, Nathan J. Schloemer, Lawrence G. Lum, Jeffrey A. Medin
Summary: CD30 is expressed on various lymphomas and malignancies, making it a potential immunotherapy target. Although anti-CD30 antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs) have shown promise, alternative treatments are still needed due to their limitations and toxicities. By developing novel anti-CD30 x anti-CD3 bispecific antibodies (biAbs), we aim to coat patient T cells ex vivo with the biAbs and re-infuse them as a safer form of cellular therapy. We have conducted comprehensive studies on the CD30 binding and tumor cell killing properties of these biAbs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Jie Wang, Chen Li, Kaijie He, Zhihui Kuang, Jia Lu, Ying Yao, Fufan He, Ninghuan Li, Li Li, Fenggen Fu, Zhihai Wu, Shuaixiang Zhou, Dian Kang, Xuan Qiu, Min Wu, Yang Liu, Xiaochao Cao, Mengqiu Xu, Bingliang Chen, Weiwei Wu, Feng Guo
Summary: This study describes a novel therapeutic antibody, IBI38D9-L, for B cell non-Hodgkin lymphomas (B-NHLs). In vitro and in vivo experiments showed that IBI38D9-L selectively kills malignant B cells and activates T cells. The preclinical data indicate that IBI38D9-L has promising efficacy and safety profiles as a potential therapeutic agent for B cell malignancies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Frans Suurs, Grit Lorenczewski, Julie M. Bailis, Sabine Stienen, Matthias Friedrich, Fei Lee, Bert van der Vegt, Elisabeth G. E. de Vries, Derk-Jan A. de Groot, Marjolijn N. Lub-de Hooge
Summary: The study developed a fully mouse cross-reactive mesothelin-targeted BiTE molecule with extended half-life, and found that it exhibited specific tumor uptake with higher uptake in lymphoid tissues. The biodistribution and tumor targeting of the molecule varied with different protein doses, with the lowest dose showing similar tumor uptake but faster blood clearance.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Nanoscience & Nanotechnology
Anmin Huang, Feixia Guo, Zhijie Yu, Pixu Liu, Shiying Dong, Yunjie Zhang, Yifan Kong, Xiuyan Kong, Ting Li, Yongde Luo, Hongping Xia, Keqing Shi, Jinglin Xia
Summary: Malignant ascites is a common symptom of peritoneal metastasis in liver cancer, and cancer immunotherapy can modulate immune cells to induce antitumor immune efficiency. In this study, engineered apoptosis-bioinspired nanoparticles (EBN) were proposed and studied for cancer immunotherapy of malignant ascites. Through in vitro and in vivo experimental validations, EBN was found to efficiently engulf tumor-associated macrophages (TAMs) and manipulate their polarization, leading to an enhanced immune cascade response. Furthermore, injection of EBN reduced ascites volume and reformed immune cell subtypes compared to other treatments.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Article
Oncology
Ulka N. Vaishampayan, Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson, Brenda Dickow, Dana Schalk, Amy Schienschang, Sarah Whitaker, Amanda Polend, Joseph A. Fontana, Elisabeth I. Heath, Lawrence G. Lum
Summary: This study aimed to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab, in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The results showed that this combination therapy had good safety and efficacy in mCRPC patients, indicating the need for further investigation.
CLINICAL CANCER RESEARCH
(2023)